{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:18:17Z","timestamp":1794028697419,"version":"4.8.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T00:00:00Z","timestamp":1553558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.00282","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T01:10:12Z","timestamp":1553562612000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":90,"title":["Paradoxical Skin Reactions to Biologics in Patients With Rheumatologic Disorders"],"prefix":"10.3389","volume":"10","author":[{"given":"Simone","family":"Garcovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Valerio","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/rheumatology\/keh437","article-title":"Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors.","volume":"44","author":"Aeberli","year":"2005","journal-title":"Rheumatology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1111\/jdv.13246","article-title":"TNF-\u03b1: a treatment target or cause of sarcoidosis?","volume":"29","author":"Amber","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2008.09.032","article-title":"Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists.","volume":"61","author":"Asarch","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/j.jaci.2018.05.015","article-title":"Paradoxical psoriasis following anti-TNF therapy in ankylosing spondylitis: a population-based cohort study.","volume":"142","author":"Bae","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jaad.2016.08.012","article-title":"Tumor necrosis factor-\u03b1 inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience.","volume":"76","author":"Brown","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2340\/00015555-0777","article-title":"Paradoxical reactions to targeted biological treatments: A way to treat and trigger?","volume":"90","author":"Brunasso","year":"2010","journal-title":"Acta Derm. Venereol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/tpj.2015.53","article-title":"Paradoxical psoriasiform reactions to anti-TNFalpha drugs are associated with genetic polymorphisms in patients with psoriasis.","volume":"16","author":"Cabaleiro","year":"2016","journal-title":"Pharmacogenomics J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.semarthrit.2017.03.008","article-title":"Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.","volume":"47","author":"Cantini","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"B9","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/art.23835","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action.","volume":"59","author":"Collamer","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis.","volume":"9","author":"Conrad","year":"2018","journal-title":"Nat. Commun."},{"key":"B11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jdermsci.2014.08.010","article-title":"Classification of inflammatory skin diseases: a proposal based on the disorders of the three-layered defense systems, barrier, innate immunity and acquired immunity.","volume":"76","author":"Dainichi","year":"2014","journal-title":"J. Dermatol. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1001\/archderm.143.2.223","article-title":"Psoriasis and pustular dermatitis triggered by TNF-\u03b1 inhibitors in patients with rheumatologic conditions.","volume":"143","author":"de Gannes","year":"2007","journal-title":"Arch. Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1093\/ecco-jcc\/jjw155","article-title":"Sarcoidosis-like lesions: another paradoxical reaction to anti-TNF therapy?","volume":"11","author":"Decock","year":"2017","journal-title":"J. Crohns. Colitis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3109\/09546634.2015.1094179","article-title":"Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.","volume":"27","author":"Delobeau","year":"2016","journal-title":"J. Dermatol. Treat."},{"key":"B15","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1001\/archderm.142.2.198","article-title":"Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor \u03b1 inhibitors.","volume":"142","author":"Deng","year":"2006","journal-title":"Arch. Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/cup.13055","article-title":"TNF\u03b1 and IL-17A are differentially expressed in psoriasis-like vs eczema-like drug reactions to TNF\u03b1 antagonists.","volume":"45","author":"Deubelbeiss","year":"2018","journal-title":"J. Cutan. Pathol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1159\/000275676","article-title":"Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases.","volume":"220","author":"Dhaille","year":"2010","journal-title":"Dermatology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/DAD.0b013e3181ef7403","article-title":"Psoriatic alopecia\/alopecia areata-like reactions secondary to anti-tumor necrosis factor-\u03b1 therapy: a novel cause of noncicatricial alopecia.","volume":"33","author":"Doyle","year":"2011","journal-title":"Am. J. Dermatopathol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/jdv.14673","article-title":"Immune response patterns in non-communicable inflammatory skin diseases.","volume":"32","author":"Eyerich","year":"2018","journal-title":"J. Eur. Acad. Dermatology Venereol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.jaad.2016.01.018","article-title":"Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases.","volume":"74","author":"Faivre","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"B21","first-page":"939","article-title":"Infliximab-induced psoriasis in treatment of crohn\u2019s disease-associated ankylosing spondylitis: case report and review of 142 cases.","volume":"12","author":"Famenini","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/rheumatology\/kep083","article-title":"Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.","volume":"48","author":"Fouache","year":"2009","journal-title":"Rheumatology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2340\/00015555-0839","article-title":"Cutaneous drug eruption with an interface dermatitis pattern due to anti-tumour necrosis factor-alpha agents: a relevant class-effect.","volume":"90","author":"Garcovich","year":"2010","journal-title":"Acta Derm. Venereol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/exd.13235","article-title":"Molecular diagnostics of inflammatory disease: new tools and perspectives.","volume":"26","author":"Garzorz-Stark","year":"2017","journal-title":"Exp. Dermatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/ced.12715","article-title":"Psoriatic alopecia.","volume":"40","author":"George","year":"2015","journal-title":"Clin. Exp. Dermatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1001\/archderm.140.12.1490","article-title":"Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors.","volume":"140","author":"Gilliet","year":"2004","journal-title":"Arch. Dermatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cytogfr.2014.10.009","article-title":"An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17.","volume":"26","author":"Grine","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/ard.2007.087288","article-title":"Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the british society for rheumatology biologics register.","volume":"68","author":"Harrison","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1002\/acr.22096","article-title":"Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the spanish registry of adverse events of biological therapies in rheumatic diseases.","volume":"65","author":"Hernandez","year":"2013","journal-title":"Arthritis Care Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/JID.2014.352","article-title":"Comparison of molecular signatures from multiple skin diseases identifies mechanisms of immunopathogenesis.","volume":"135","author":"Inkeles","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2500\/aap.2017.38.4085","article-title":"Management of adverse reactions to biologic agents.","volume":"38","author":"Isabwe","year":"2017","journal-title":"Allergy Asthma Proc."},{"key":"B32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1080\/09546630802441234","article-title":"Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases.","volume":"20","author":"Ko","year":"2009","journal-title":"J. Dermatol. Treat."},{"key":"B33","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/ddg.12032","article-title":"Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis.","volume":"11","author":"Kowalzick","year":"2013","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1111\/j.1440-0960.2011.00863.x","article-title":"Development of cutaneous sarcoidosis during treatment with tumour necrosis alpha factor antagonists.","volume":"53","author":"Lamrock","year":"2012","journal-title":"Australas. J. Dermatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3109\/08916934.2013.873414","article-title":"Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.","volume":"47","author":"Marzano","year":"2014","journal-title":"Autoimmunity"},{"key":"B36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12016-017-8621-8","article-title":"A comprehensive review of neutrophilic diseases.","volume":"54","author":"Marzano","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.semarthrit.2008.11.003","article-title":"Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new &quot;class effect&quot; paradoxical phenomenon. two case reports and literature review.","volume":"39","author":"Massara","year":"2010","journal-title":"Semin. Arthritis Rheum."},{"key":"B38","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000342503","article-title":"Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature.","volume":"225","author":"Os\u00f3rio","year":"2012","journal-title":"Dermatology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1073\/pnas.0408506102","article-title":"Cross-regulation of TNF and IFN-alpha in autoimmune diseases.","volume":"102","author":"Palucka","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B40","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/RHU.0b013e3181efa190","article-title":"Tumor necrosis factor-alpha antagonist-induced sarcoidosis.","volume":"16","author":"Robicheaux Clementine","year":"2010","journal-title":"J. Clin. Rheumatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.det.2015.03.005","article-title":"Reactive granulomatous dermatitis: a review of palisaded neutrophilic and granulomatous dermatitis, interstitial granulomatous dermatitis, interstitial granulomatous drug reaction, and a proposed reclassification.","volume":"33","author":"Rosenbach","year":"2015","journal-title":"Dermatol. Clin."},{"key":"B42","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.jbspin.2012.06.010","article-title":"Successful effect of tocilizumab in anti-TNF-alpha-induced palmoplantar pustulosis in rheumatoid arthritis.","volume":"79","author":"Rueda-Gotor","year":"2012","journal-title":"Joint. Bone. Spine"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1002\/art.21233","article-title":"Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B44","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/MPG.0b013e31828390ba","article-title":"Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric crohn disease and a potential association with IL-23 receptor polymorphisms.","volume":"56","author":"Sherlock","year":"2013","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"B45","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3109\/14397595.2014.985812","article-title":"Successful treatment with tocilizumab of a psoriasiform skin lesion induced by etanercept in a patient with juvenile idiopathic arthritis.","volume":"25","author":"Shimizu","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00296-017-3861-8","article-title":"Pyoderma gangrenosum and pyogenic arthritis presenting as severe sepsis in a rheumatoid arthritis patient treated with golimumab.","volume":"38","author":"Skalkou","year":"2018","journal-title":"Rheumatol. Int."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/bjd.16126","article-title":"Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics.","volume":"178","author":"Stoffel","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/1346-8138.13762","article-title":"Cutaneous side-effects of biologics in immune-mediated disorders: a histopathological perspective.","volume":"44","author":"Succaria","year":"2017","journal-title":"J. Dermatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","article-title":"Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-\u03b3-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment.","volume":"63","author":"Tillack","year":"2014","journal-title":"Gut"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview.","volume":"2","author":"Toussirot","year":"2016","journal-title":"RMD Open"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010455.pub2","article-title":"Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.","volume":"9","author":"van Herwaarden","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s10067-007-0733-8","article-title":"Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis.","volume":"26","author":"Vandevyvere","year":"2007","journal-title":"Clin. Rheumatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1001\/archderm.138.9.1258","article-title":"Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern.","volume":"138","author":"Vergara","year":"2002","journal-title":"Arch. Dermatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/cei.12808","article-title":"Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis.","volume":"185","author":"Verwoerd","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1586\/eci.09.18","article-title":"Paradoxical adverse effects of anti-TNF-\u03b1 treatment: onset or exacerbation of cutaneous disorders.","volume":"5","author":"Viguier","year":"2009","journal-title":"Expert Rev. Clin. Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/ard.2007.075663","article-title":"Granuloma annulare induced by anti-tumour necrosis factor therapy.","volume":"67","author":"Voulgari","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","article-title":"Tumor necrosis factor-\u03b1 inhibitor-induced psoriasis or psoriasiform exanthemata.","volume":"9","author":"Wollina","year":"2008","journal-title":"Am. J. Clin. Dermatol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00282\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T01:10:15Z","timestamp":1553562615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00282\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,26]]},"references-count":57,"alternative-id":["10.3389\/fphar.2019.00282"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.00282","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,26]]},"article-number":"282"}}